THERAPEUTICS SYMPOSIUM 2021

GLOBAL THERAPEUTIC ALLIANCE OVERVIEW

AN ONLINE EVENT ON JUNE 22
GLOBAL THERAPEUTIC ALLIANCE

The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration.

Research in the Milner Therapeutics Institute is funded by:

Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p2), and the Alliance has been expanded with the Affiliated Company (p8) and Affiliated Institutions scheme (p36) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge.

The Affiliated Venture Partners programme, operational since October 2017, provides mentoring and potential funding for the start-ups within the Start Codon Accelerator and the Frame Shift Bio-incubator.
MILNER THERAPEUTICS CONSORTIUM

The Milner Therapeutics Consortium is an academic-industry partnership, active since June 2015. This is underpinned by a Consortium agreement, designed to facilitate speedy exchange of reagents and fund collaborative research.

ASTEX PHARMACEUTICALS

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in development under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan. Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka — people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

For more information about Astex Pharmaceuticals, please visit www.astex.com

For more information about Otsuka Pharmaceutical, please visit www.otsuka.com/en/
Partnerships and collaborations drive medical innovation today. Our approach to open innovation helps us collaborate with like-minded scientists at the interface of scientific disciplines where true creativity and innovation occurs.

Our scientists in discovery genomics, antibody engineering, antibody technology and screening sciences are already working side by side with scientists from the Medical Research Council and Cancer Research UK.

By being headquartered in Cambridge, we also bring business professionals into the ecosystem. In addition to our science and research collaborations, we support a number of business mentoring initiatives to help UK biotech entrepreneurs advance their business ideas. This includes several programmes run by the University of Cambridge Judge Business School’s Entrepreneurship Centre, including Accelerate Cambridge.

AstraZeneca has been supporting the Accelerate Cambridge programme since March 2015. Over 70 AstraZeneca mentors are now involved in the programme and around 75 start-ups have benefitted from their experience so far.

We have over 150 collaborations underway with the University of Cambridge including PhD and PostDoc programmes. We also work with Addenbrooke’s Hospital, Royal Papworth Hospital, The Medical Research Council Laboratory of Molecular Biology (LMB), The Cancer Research UK (CRUK) Cambridge Institute, The Wellcome Sanger Institute, Microsoft and members of the technology sector.

At Bristol Myers Squibb, we are inspired by a single vision — transforming patients’ lives through science. We focus on the science that drives meaningful change for patients, for their carers and loved ones, and for the communities and societies we share. We are a global biopharmaceutical company with leading franchises in oncology, haematology, cardiology and a strong presence in immunology, fibrosis and specialty medicine. We are committed to continuing innovation and have a broad late-stage and robust early-stage pipelines, supported by our cutting edge technologies and discovery platforms. We are a global company, headquartered in the US, with industry-leading research and development, medicine development, delivery and commercial operations in the UK and Ireland.

In our facilities across the UK and Ireland, more than 900 members of Bristol Myers Squibb staff work to develop and deliver innovative medicines that transform people’s lives.

Our values of passion, innovation, urgency, accountability, inclusion and integrity are central to who we are, what we do and how we do it. They inspire us every day and unite us with our colleagues and partners here in the UK and Ireland and around the world.
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in therapeutic areas with high unmet medical needs, including oncology and neurology.

Our External Innovation strategy aims to contribute to human health care by prioritising disease prevention, prediction, and treatment based on global investments and research collaboration. Our Neurology Global External Innovation team is led from the EMEA Knowledge Centre (EKC) in Hatfield, Eisai’s regional headquarters. The site also houses neurology research laboratories and oncology and neurology clinical research as well as a secondary manufacturing facility. Our flexible approach allows us to engage in a number of different academic partnership models, including research sponsorship for specific programmes, joint research programmes, scientific start-up programmes, and ‘Open Innovation’ models involving public/private consortia.

Our mission is clear, we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy, in everything we do.

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Lilly External Innovation and Business Development teams are always on the lookout for the breakthrough ideas for novel therapeutics and partnerships that complement our internal pipeline. Working with Lilly means your team will have access to more than 6,000 scientists who are recognized worldwide for their deep expertise and advanced research capabilities. Our evaluation provides an independent, objective review of molecules, processes and technologies. To find out about our scientific areas of interest and how to collaborate with us please visit https://www.lilly.co.uk/discovery/scientific-partnering
FERRING PHARMACEUTICALS

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical company committed to helping people around the world build families and live better lives. Ferring Pharmaceuticals has more than 6500 employees operating in 56 countries and have products available in 100 countries worldwide. In 2019 the sales reached EUR 2 Billion.

Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology/uro-oncology. We have a fully integrated R&D organization with more than 700 scientists and use around 20% of our annual revenue on R&D. Today, over one third of the company’s research and development investments goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Our R&D mindset is focused on identifying and developing innovations no matter their source. As a global pharmaceutical company, we pursue strategic partnerships that can leverage technologies and capabilities. Our goal is to create long-term mutually beneficial partnerships that advance science and bring innovative medicines to patients around the globe.

Key indications:
- Reproductive medicine & maternal health: Infertility (female & male), Implantation Support, Preterm Birth, Preeclampsia
- Gastroenterology: Crohn’s disease, Ulcerative Colitis, Celiac disease
- Uro-oncology: Bladder cancer, Urothelial cancer, Prostate Cancer
- Strong interest in the microbiome and immunology across all three therapeutic areas

GSK

Less than 10% of drugs undergoing clinical testing become medicines. We know that medicines with genetic validation succeed nearly twice as often as those without. Our approach is focused on science related to the immune system and the use of human genetics to help us accelerate the pace at which we develop and deliver transformational medicines.

Advanced technologies are central to our new R&D approach. We are developing a core capability in artificial intelligence and machine learning, to enhance our ability to interpret and understand genetics and genomic data. We are also investing in functional genomics, applying techniques for gene modification such as CRISPR technology, to help discover and validate potential targets.

Partnerships. The industry needs more innovative medicines for patients and the future is exciting, but we know we do not have all the ideas and continue to look outside our four walls for medicines and vaccines with the potential to become transformational. We’d love to talk to you if you think your idea has promise.

COVID-19. GSK is supporting global efforts to tackle the virus. Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products. For further details see: www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov/

Annual report:
Johnson & Johnson Innovation seeks to positively impact human health through innovation.

Johnson & Johnson Innovation in EMEA focuses on accelerating early stage innovation across the region and forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer health sectors.

In our Pharmaceuticals sector we are divided into six therapeutic areas that run disease and pathway focused portfolios, which are fuelled by world class functions. In our areas of focus*, we drive research from inception/idea through new indications for marketed products until loss of exclusivity.

Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators — through our Innovation Centre in London, UK, our incubator JLABS @ BE in Belgium, our strategic venture capital arm Johnson & Johnson Innovation JJDC, Inc. and for later stage collaborations our Janssen Business Development teams — to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in consumers and patients.

For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com or follow us on Twitter @jnjinnovation

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Many of those concepts are advanced in collaboration with key leaders across the scientific spectrum via our range of collaborative models (www.pfizer.com/science/collaboration). Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.

For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

To learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer.

* Cardiovascular; Metabolism & Retinal Disease; Immunology; Infectious Diseases and Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Do you believe that your research has potential to deliver an innovation that improves healthcare and provides socio-economic impact beyond academia?

If your answer is ‘yes’, Shionogi is here to work with you to realise the potential of your research.

Shionogi is a research-intensive global pharmaceutical company having its roots in Japan. The company’s achievement in delivering many life-saving healthcare products stems from successful collaborations with partners in academic communities and biotech/pharma companies. As scientific research does not happen in isolation, Shionogi researchers pursue discovery through collaborations with scientists around the globe who share their passion in bringing innovations to the real world. Partnership with Shionogi involves working in a cross-cultural/international environment, setting a research objective with a view of therapeutics development, and building a shared commitment to deliver a win-win outcome.

Shionogi seeks research partners in its core therapeutic areas including infectious diseases and neuroscience (pain, psychiatric disorders, dementia); additionally, in areas of healthy aging, metabolic disorders and immunoncology. Shionogi also pursues research collaborations in new development areas including nucleotide and peptide therapeutics, microbiome therapeutics, AI-powered/data-driven drug discovery, and digital health technologies.

Working together, we can deliver a significant impact on improving health and quality of life.

For more information about Shionogi, please visit: https://www.shionogi.com/global/en/
AFFILIATED COMPANIES

The Affiliated Company scheme, established in October 2016, now includes 51 organizations which bring diverse expertise and resource to the Milner network.

PHARMA & BIOTECH

* Small and medium-sized enterprises
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading antibody expertise. By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With twelve sites globally, many of Abcam’s 1,100 strong team are co-located in the world’s leading life science research hubs, complementing a global network of services and support.

Contact: www.abcam.com

AI VIVO is a Cambridge-based company providing an intelligent systems pharmacology platform to accelerate drug discovery and development. We uniquely combine systems biology, machine learning and AI to build a disruptive technology that enables unexpected discoveries and orders-of-magnitude gains in scalability, speed and cost. Our team of systems biologists, system pharmacologists and machine learning experts believe that biology, health and disease are all about balances and imbalances. We developed a proprietary discovery pipeline to represent 1) balances in a healthy normal condition, and 2) imbalances induced by diseases, treatments and the microbiome.

We then use our optimised AI-driven prediction engine to link these balances and imbalances with mechanisms, indications and chemical space. We use this data to alleviate pathological imbalances and restore stability with unprecedented accuracy by 1) identifying novel unexpected modulation strategies (e.g. mechanisms, pathways, targets), and 2) predicting corresponding modulators (e.g. compounds, peptides, metabolites). This disruptive platform speeds up and de-risks the discovery process by concurrently identifying multiple candidates and pre-selecting the best opportunities through experimental validation. We then offer successful validations as IP-protected data packages to be acquired or in-licensed.

AI VIVO is currently engaged in predicting, validating and developing novel mechanisms and pathways for selected disease areas; drug combination candidates for drug repositioning and life cycle management; microbiome-based solutions and product development. We partner with pharma, biotech, CROs and academics.

Contact: info@aivivo.co | www.aivo.co
ALLOY THERAPEUTICS

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA with European labs in Cambridge, UK. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Contact: info@alloytx.com | www.alloytx.com

AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Contact: www.amgen.com
Arctoris is a platform company founded and headquartered in Oxford, UK that conducts integrated drug discovery projects from idea to IND. Thanks to end-to-end automation of research processes from experiment design and execution to full data/metadata capture and analysis, Arctoris is the ideal partner for biotech and pharma companies that want to make the right decisions at the right time. Combining the experience of seasoned biotech and pharma veterans with its proprietary tech platform, Arctoris is the next step in drug discovery evolution.

Ulysses, the unique technology platform developed by Arctoris, enables the company's clients and partners to conduct their R&D — from target validation via hit finding and hit-to-lead to lead optimization and beyond — significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates more than 100 times more datapoints per assay than industry standard, making critical information in cell and molecular biology as well as biochemistry/biophysics available earlier, leading to higher success rates and an accelerated progression of programs towards the clinic.

Arctoris offers both fee-for-service and risk-share agreements in small molecule and biologics discovery, and is trusted by biotech and pharma companies in the US, UK, Germany, Australia, Korea, Hong Kong, and many other countries.

Contact: Versha Prakash | versha.prakash@arctoris.com
www.arctoris.com

BenevolentAI

Benevolent AI, founded in 2013, creates and applies AI technologies to transform the way medicines are discovered and developed. The company seeks to improve patient's lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated. The company has developed the Benevolent Platform™ — a discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients.

Contact: www.benevolent.ai
BioAscent

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon/MSD R&D site in Newhouse, Scotland.

We specialise in working with academic groups and biotechs to successfully progress their small molecule drug discovery programs. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and compound management, all with access to a library of 125K lead-like compounds via Compound Cloud.

Contact: info@bioascent.com | www.bioascent.com

Biomax Informatics

Biomax Informatics provides services and software solutions for efficient decision-making and knowledge management at the intersection of life sciences, healthcare and information technologies. Biomax facilitates digital transformation within biotech, pharma, agriculture, food and chemical industries as well as research institutes.

Biomax offers a range of standard products, based on the core technology knowledge management platform BioXM™, which are synergistically interrelated.

- AILANI™, the Artificial Intelligence LANguage Interface, provides unique semantic search capabilities that catalyze digital change and accelerate the innovation cycle.
- NeuroXM™ is the one-stop-shop to decipher brain physiology.
- The Clinical Integration System ensures access to real world evidence data, which is critical to effectively and robustly train Artificial Intelligence to support clinical decisions at the point of care.

With more than 20 years of experience and around 50 employees — including numerous life scientists, data scientists and software developers with a scientific background — Biomax is a competent partner.

Participation in multinational research projects keeps the Biomax team up-to-date with the latest research and technology and ensures that Biomax delivers state-of-the-art solutions to all customers.

Founded in 1997, Biomax is ISO 9001 and ISO 27001 certified and is headquartered in Planegg near Munich, Germany.

Contact: info@biomax.com | www.biomax.com
Biorelate was founded in 2014 from cutting-edge scientific research into how biomedical curation can utilise existing dark knowledge to accelerate future drug discovery. Staying true to our roots, we have always believed that a better understanding of today’s science can bring forward the next generation of life-saving therapeutics being developed by world leading researchers.

Since then, Biorelate has developed a fully automated NLP/AI platform to mine cause-and-effect data buried within biomedical literature, patents, grants, clinical trials, and other relevant sources. It is estimated that over 80% of all biomedical knowledge is still held in unstructured text, making it extremely difficult to access and use in analytical workflows. This is a huge resource of untapped knowledge as it is currently unavailable within public or proprietary databases.

At Biorelate we believe accessing the most up-to-date insights from research is essential in accelerating the world’s most promising biomedical innovations. The biomedical research industry is facing a major challenge in curating and understanding the huge volume of growing and evolving new data. As a result, new drugs and life-saving innovations are being developed erroneously without a full grasp of today’s science.

Our technology, Galactic AI™, seeks to solve these issues by using artificial intelligence to automatically curate and provide insight to crucial aspects of scientific research that would otherwise be lost.

Contact: www.biorelate.com

The widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types has been restricted by complex and suboptimal differentiation protocols. The Bit Bio novel cellular reprogramming approach supported by a uniquely engineered genetic switch, opti-ox, is able to largely overcome these restrictions. This proprietary technology enables homogeneous and efficient differentiation of entire hiPSC cultures through tightly controlled expression of selected transcription factors. opti-ox reprogramming enables the consistent manufacture of homogenous and mature hiPSCs derived functional cells within days, offering access to the highest quality cellular models with simple protocols.

‘Bit Bio’ represents the two fields — coding and biology — that determine the identity of every human cell. Ultimately, bits are the building blocks of code, just as cells are the building blocks of life. This is reflective of what Bit Bio does: precise reprogramming of human stem cells. Bit Bio’s mission and focus are to enable a new generation of therapies through democratising access to consistent and functional human cells. This will improve research and drug discovery, lower the cost and extend the application of cell therapies.

Contact: www.bit.bio
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on the research and development of disease modifying therapeutics candidates for Alzheimer’s disease (AD), Parkinson’s disease (PD) and Type 2 Diabetes (T2D). Through its proprietary drug discovery programs Cantabio is targeting the reduction of protein aggregation, oxidative and glyoxal stress, which are believed to be some of the main causes of AD and PD. Cantabio’s research strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery platform to develop small molecule pharmacological chaperones for clinical trials. These small molecule pharmacological chaperones act to stabilize the native functional form of selected protein targets against misfolding when they lose their function and/or become toxic.

In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions. Cantabio is specifically developing the following therapeutic programs: (1) CB101: small molecule pharmacological chaperones targeting the DJ-1 protein for PD; (2) CB201: engineered cell-penetrant DJ-1 protein for T2D; (3) CB301: small molecule pharmacological chaperones targeting the Tau protein for AD. The company has operations in Silicon Valley (USA), Cambridge (UK) and Budapest (Hungary), where multidisciplinary in-house R&D is carried out in our laboratory facilities.

Cantabio also has strong academic links with a number of academic institutions including the University of Cambridge, allowing cutting edge academic research support to Cantabio’s therapeutic programs.

Contact: info@cantabio.com | www.cantabio.com

Cell Guidance Systems’ primary focus is PODS®, a protein delivery technology which generates zero-order delivery kinetics over periods up to two months.

Protein instability is a recurring problem in the development of effective protein drugs, diagnostic assay controls, and delivery of effective vaccines. Cell Guidance Systems’ PODS platform technology utilizes a patented technology to produce polyhedrin crystals containing constrained target proteins. This production process results in proteins with significantly enhanced stability in storage and zero-order release kinetics. Working in collaboration with world-class research institutes and other companies, Cell Guidance Systems is developing PODS proteins for use as therapeutics and cell survival agents for regenerative medicine.

Contact: Michael Jones | michaeljones@cellgs.com
www.cellgs.com
CST is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. As scientists ourselves, we believe an antibody is only as good as the research it enables. For this reason, we are actively engaged in the development of technologies to facilitate signaling analysis and mechanistic cell biology research. And the same scientists who produce and validate our primary antibodies are available to provide technical support for customers. In this way, we are able to supply customers with both the reagents and the information they need to achieve consistent, reliable results at the research bench.

**Contact:** Melvin Jose | melvin.jose@cellsignal.com  
www.cellsignal.com

Censo Biotechnologies is a specialist discovery service company supporting the discovery and development of new targeted treatments for neurodegenerative, neuroinflammatory and rare diseases, by using stem cell technology to predict how drugs will behave across a given population. Censo provides access to existing human iPSC lines, and ethically sources human tissue, both healthy and with clinically relevant disease specific mutations, to custom create new clinically relevant human patient iPSC lines for diseases such as Alzheimer’s, Parkinson’s, ataxias and ALS. Using highly reproducible differentiation protocols to create cell types like microglia, astrocytes, cortical and sensory neurons, we offer both customised and standard phenotypic assays to deliver disease relevant compound characterisation, and studies of genotype-phenotype relationships, providing our clients with an understanding of human therapeutic efficacy and patient population therapeutic response variability.

**Contact:** enquiries@censobio.com | www.censobio.com
CYCLICA

From molecule to medicine, Cyclica embraces the complexity of disease. With deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs. Our work spans dozens of collaborations with large pharma and biotech as well as several joint ventures. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labor at the intersection of our collective expertise.

To learn more about Cyclica and how we partner, please visit us online.

Contact: www.cyclicarx.com

CYTIVA

We are a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We are nearly 7000 associates with operations in 40 countries. We are a trusted partner to customers who do things ranging from fundamental biological research to making life-saving vaccines, biologic drugs and novel cell and gene therapies. Some of our customers use our products in industries outside of biological research.

What we believe: Our vision is a world in which access to life-changing therapies transforms human health. Our everyday work leads us step by step toward this vision.

What we do: Our mission is advancing and accelerating therapeutics. We supply the tools and services — the pots, pans, soups and sauces — that help our customers do their work better, faster, and safer. Some of our products, such as filters, can also support a range of applications in industries outside of biological research. Everything we do is essential to the entire process — from start to finish and in between. We advance the work of our customers for better patient outcomes.

Contact: www.cytivalifesciences.com

TESTA CENTER

The Testa Center is operated as a non-profit company, owned by Cytiva. It is a major initiative between the Swedish government and Cytiva to secure the growth of life science industry and its manufacturing capabilities. The main objective for the Testa Center is to bridge the gap from discovery to industrialization.

Contact: contact@testacenter.com
| https://testacenter.com
DefiniGEN has world-leading expertise in the area of iPSC product and metabolic disease modelling. The company has a unique platform technology for generating phenotypically validated human cell disease models for a range of rare metabolic and liver diseases, to optimize preclinical drug discovery. DefiniGEN’s proprietary OptiDIFF platform generates terminally differentiated human cells of endodermal lineage from iPSCs. We provide iPSC-derived hepatocytes, pancreatic cells, and intestinal organoids from healthy and diseased donors which closely resemble human primary cells.

Off-the-shelf products include:
- Alpha-1 antitrypsin deficiency
- Glycogen storage disease type 1a
- Familial hypercholesterolemia
- MODY3 Diabetes
- Neonatal Diabetes

In addition, the application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro human cell products enabling safer and more effective treatments. This technology platform can be combined with our cutting edge CRISPR gene-editing services to produce a wide range of bespoke validated disease model cell products enabling pharmaceutical companies to effectively reprofile and reposition their libraries.

**Contact:** Richard Willock | richard.willock@definigen.com
www.definigen.com

Diagenode provides complete solutions for epigenetics research in immuno-oncology, neuroscience, and more. Our comprehensive approach to gain insights into RNA, DNA, and chromatin analysis from solid tumor to liquid biopsy samples with experimentally-validated, easy-to-use solutions and services give researchers the success to move from research to translational and clinical applications.

Diagenode’s product portfolio includes innovative shearing solutions for a number of applications such as DNA shearing from 150bp to 100kb, chromatin shearing, RNA and protein extraction, and cell lysis. In addition, we offer reagent kits and high quality antibodies to streamline DNA methylation, ChIP, ChIPmentation, ChIP-seq, and ATAC-seq workflows. The company’s latest innovation includes single cell ATAC-seq services powered by Bio-Rad’s dd-Seq technology promising highest possible capture efficiency and greater number of unique fragments.

In addition, our Epigenomics Profiling Services provide epigenome-wide drug discovery, transgenerational studies, epigenetic biomarker identification including cancer biomarkers, and functional epigenomics.

**Contact:** info@diagenode.com | www.diagenode.com
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.

Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets.

Domainex offers a range of services including:
- Medicinal chemistry (including SBDD)
- FragmentBuilder (Domainex’s proprietary fragment screening platform)
- Computational chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform)
- Assay development and screening (biochemical, biophysical and cell assays)
- iPSC and immune cell biology
- Protein production
- CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains)
- Analytical chemistry
- X-ray crystallography services

Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.

Contact: enquiries@domainex.co.uk
www.domainex.co.uk

Drishti Discoveries is a preclinical stage gene therapy company. Drishti is using a clinically validated gene modulation technology to express proprietary engineered miRNA molecules within the cell, converting the cells into RNAi producing factories.

Our strategy is to apply the validated technology to silence validated targets to develop in vivo gene therapy for diseases with high unmet need.

Drishti’s current focus areas include:
1. Genetic modifiers of rare diseases, and
2. Genetic diseases caused by dominant mutations

Drishti’s lead programme is targeting a genetic modifier of TDP-43 toxicity in ALS. We have identified and in vivo validated a lead candidate for this programme. We are currently developing non-clinical efficacy evidence.

Moving forward, Drishti is developing a pipeline of programmes relevant to diseases of the nervous system.

Contact: www.drishtidiscoveries.com
EAGLE GENOMICS

Eagel Genomics' award-winning AI augmented knowledge discovery platform is revolutionising how scientists conduct life sciences research and is bridging the gap between data and new insights in a rapid, systematic and traceable way. It puts data science at the fingertips of biologists to drastically reduce time and cost of research, enabling customers to achieve radical productivity improvements and true data-driven discovery. Eagle Genomics are thought leaders in life sciences smart data management and analysis. Over the last decade, we have collaborated with a range of blue-chip clients in the healthcare, personal care and agritech sectors, enabling them to deliver game-changing products and technologies into their respective markets. At Eagle Genomics, we innovate at the intersection of biology, data science and bioinformatics. We combine our knowledge in these fields with best in class enterprise software skills to achieve an audacious goal — to develop the enterprise information architecture for the genomics era. We are also proud of our strong links to research and development in the critical emerging markets of human genomics and microbiomics. We are headquartered in the epicentre of genomic research at the Wellcome Campus in Cambridge, with locations in London’s Knowledge Quarter, the New York Genome Centre and Station F in Paris.

Contact: contact@eaglegenomics.com
www.eaglegenomics.com

ENHANC3D GENOMICS

Enhanc3D Genomics is a functional genomics spinout company from the Babraham Institute (Cambridge, UK) leveraging a disruptive technology to profile three-dimensional (3D) genome folding at high resolution. Understanding DNA organisation and long-distance interactions allows us to link gene enhancers and non-coding genetic variants to their target genes and holds promise to unlock disease-related genetics for therapeutic discovery.

Contact: www.enhanc3dgenomics.com
**EUROFINS DISCOVERY**

Eurofins Discovery accelerates the critical drug discovery endeavor for our global clients through decades of experience and flexible solutions. We provide comprehensive solutions from assay-ready services to DiscoveryOne™ integrated programs: chemistry, *in vitro* safety and efficacy phenotypic assays, ADME-tox and pre-clinical pharmacology. From our DiscoveryOne™ integrated programs to tailored and assay ready services; chemistry, *in vitro* safety and efficacy phenotypic assays, ADME-Tox and pre-clinical pharmacology.

Whether you have needs to outsource or perform research in-house, Eurofins Discovery Services and Eurofins DiscoverX product solutions enables research, drug discovery and post market validation.

**Contact:** info@eurofins.com | www.eurofins.com

**GENEDATA**

Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning, user-friendly platforms and deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production.

The Genedata portfolio of advanced software solutions is built on open, enterprise-level client-server architecture, which can be deployed to a variety of infrastructures, including on-premises or cloud-based installations. Genedata solutions deliver a high degree of built-in business logic, integration, performance, and scalability to researchers, scientists, and managers. Genedata also offers a range of services and support, from installation and customization to global roll-out support, training, data analysis, application consulting and IT consulting services, all tailored to clients’ specific needs. Highly skilled professionals bring extensive domain knowledge and experience to your organization.

Today, the world’s leading pharmaceutical, agrochemical, and biotechnology companies, as well as some of the most innovative life science research institutions rely on Genedata. Genedata recently released its latest version of Genedata Profiler®, the enterprise solution of choice for efficient and effective omic-based translational and exploratory clinical research that enables global research organizations to achieve their vision of precision medicine. Breaking down data silos and allowing controlled access to every research team member, the platform provides self-service data analytics that generate valuable scientific insights at scale, while enabling compliance with increasingly complex data privacy laws and regulatory requirements.

**Contact:** www.genedata.com
Genestack brings together bioinformatics and software development expertise to provide solutions for data and metadata management, as well as analysis pipelines and a range of interactive visual analytics tools.

Our portfolio of products and services includes a combination of off-the-shelf modules, customisation, and new apps prototyping. We draw on decades of industry and academic experience to provide customers with tailored data management solutions and scientific consultancy.

We work with clients in the pharmaceutical, consumer goods, biotechnology and healthcare industries to help them get the most out of their data and maximise the return on investment into data production. We aim to make the lives of people who do bioinformatics simpler. Our goal is to help our users leverage high-throughput multi-omics data and fast-track drug discovery, precision medicine and bioinformatics research in the post-genomic era.

Currently we are releasing Omics Data Manager (ODM), a data management system for multi-omics, biological and healthcare data. ODM is a software product that enables its users to create a FAIR data catalogue, by solving common pain points in data management such as data silos, lack of metadata standards, and unclear data relationships. ODM is the result of a fruitful collaboration with a top pharmaceutical company.

Contact: info@genestack.com | www.genestack.com

Genome Biologics was founded in 2017 on the strength of a state-of-the-art integrated RNAi and NCE drug discovery and development platform. The central disruptive quality of Genome Biologics is its ability to translate AI/Big data-driven disease signature identification and mapping to the pre-clinical drug validation realm, through generation of in vitro and in vivo precision disease models to more accurately identify and validate efficacious therapeutic RNAi and NCEs for cardiovascular and cardiometabolic disease. In taking this unparalleled approach, Genome Biologics has developed a rich therapy pipeline in Cardiovascular Disease — Genome Biologics drug assets improve diseased heart function by employing a number of strategies including metabolic modulation and the activation of cardiac regeneration.

Contact: www.geneomebiologics.com
info@genomebiologics.com
Healx is an AI-powered, patient-inspired tech company, accelerating the discovery and development of treatments for rare diseases. There are 7,000 known rare diseases that affect 400 million people across the globe but only 5% of those conditions have approved treatments. Healx’s mission is to use AI to identify and progress novel rare disease treatments at scale.

To do this, Healx created Healnet, its AI-driven drug discovery platform. Healnet integrates data from multiple sources, including biomedical research, scientific literature and Healx’s own curated proprietary information, to form the world’s most detailed rare disease knowledge graph. This graph is then analysed by the team’s innovative AI and computational biology models, to identify existing drugs that may be repurposed and combined to treat rare diseases. This approach, combined with patient insight and drug discovery expertise, means treatments can be found more quickly, efficiently and cost-effectively than traditional drug discovery methods allow.

Healx was founded in 2014 in Cambridge, UK, by Dr Tim Guilliams, a Biochemical Engineer and tech entrepreneur, and Dr David Brown, co-inventor of Viagra and former Global Head of Drug Discovery at Roche.

Contact: www.healx.io | info@healx.com

Immundnz is a UK-based specialist immunology company providing customised and experimental immunology services using *in vitro* and *ex vivo* human cell models for preclinical drug research and development. Key areas that we focus on are immuno-oncology, inflammation, auto-immune disease and the assessment of immune risk, immune safety and immunotoxicity in order to understand the effect of novel compounds on the immune system.

Contact: Masih Alam | masih.alam@immundnz.com www.immundnz.com
INTELLEGENS

Our mission is to help clients accelerate innovation by using our unique deep learning solutions to extract valuable information from existing processes and data.

Our technology originated from the Cavendish Laboratory, University of Cambridge. At Intellegens, we have further developed this work to build a unique Artificial Intelligence (AI) toolset that can train deep neural networks from sparse or noisy data. These capabilities are available through our first commercial product, Alchemite™. Our Cambridge-based development team continues to extend and improve the Alchemite™ software based on feedback from our customers and partners.

Our Alchemite™ tools can help with any problem where you need to understand and apply sparse and noisy data — from business decision-making to healthcare delivery. A key focus has been on problems in discovery and development, particularly where there is a need to focus or apply results from experimental programs in order to innovate, faster, and at lower cost. From the first use of our algorithms on designing a novel alloy for aerospace applications, we’ve gone on to tackle applications in areas including formulation design, chemicals, drug discovery, materials, batteries, and optimising manufacturing processes.

As well as providing value to our customers through the Alchemite™ software products, our deep learning technology can be embedded in third-party platforms to help with problems related to sparse and noisy data.

Contact: info@intellegens.ai | www.intellegens.ai

JW PHARMACEUTICAL

Taking the first step in 1945, JW Pharmaceutical has found the market for domestic therapeutic drugs based on its philosophy of respecting life and pioneering spirit. JW Pharmaceutical established a comprehensive research center in 1983 based on accumulated technology and outstanding capability. Based on a long history and know-how in treatment and medicine, JW Pharmaceutical are constantly researching and developing innovative new medicine. We are targeting the diseases with high demand for medical unmet needs, concentrating on the development of innovative new medicines using JW’s unique technology, and conducting research activities in line with global trends through open innovation. Research directions are Innovation R&D, Nutrition therapy and Diagnostics. 22 kinds of pipelines are developing, in disease areas including cancer, immunological disease, cardiovascular system, metabolic disease, regenerative medicine, rare and eye disease. We are committed to making our society bright and healthy by producing and supplying innovative technologies, products and services which will support healthy lives, and will pursue the satisfaction and happiness of customers, shareholders and the employees through our trustworthy activities.

Contact: Kyoung-Wan Cho | kwcho@jw-pharma.co.kr
www.jw-pharma.co.kr
LIFE BIT

Lifebit is democratising the analysis and understanding of genetic big data to leap-forward cures, disease prevention, and our quality and understanding of life.

Lifebit solves the challenge of analysing vast amounts of distributed and previously inaccessible genomics data. We do this with one end-to-end operating system platform that enables federated analysis and powerful automation, no matter where data resides, no matter what compute infrastructure is employed.

Lifebit’s operating system is designed for data security. Organisations and researchers are never forced to move sensitive data from one place to another. Lifebit CloudOS is the first fully federated genomics platform that integrates and accommodates all best practices and compliance models. Data privacy and security are always assured and collaboration across teams is seamless.

Whether drug discovery, diagnostics, predicting drug response, or developing personalised wellness models, Lifebit’s technology creates new collective understandings from complex distributed data. With our partners and customers, we are helping to form a more integrated landscape of knowledge that enriches life and enables tangible breakthroughs.

At Lifebit, machine learning and AI underpin our solutions and processes. Targeted discovery, design, trials and treatments are empowered and propelled by machine learning techniques. Lifebit AI Engine enables a truly intelligent approach to developments in all areas of life sciences, drug discovery and precision medicine.

Contact: hello@lifebit.ai | www.lifebit.ai

MEDANNEX

Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a Series B fundraise, and supported by both Scottish Enterprise and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

We are currently preparing to initiate a First-in-Human clinical oncology study with our lead antibody, MDX-124, later this year. Our non-clinical therapeutic development programme for autoimmune diseases continues in parallel.

Medannex won both 'Investment of the Year' and 'Outstanding Skills Development' at Scotland’s Life Sciences Annual Awards 2021.

Contact: info@medannex.org | www.medannex.org
MICROBIOTICA

The microbiome represents a paradigm shift that affects every aspect of biomedicine: our gut bacteria control health and disease, and can themselves be a novel type of medicine. Since its foundation in late 2016, Microbiotica has shown itself to be a global leader in this exciting new sector based on its unique platform which brings precision medicine to the microbiome. In June 2018 it signed a strategic alliance with Genentech in IBD worth $534m, the largest microbiome deal at the time. In the same month, the company signed a collaboration with University of Adelaide to access Ulcerative Colitis clinical samples. These deals demonstrate the remarkable speed with which Microbiotica is building its position in the microbiome field while simultaneously advancing its pipeline.

Microbiotica’s platform, based on ground-breaking science developed at the Sanger Institute, enables unprecedented precision in identifying bacteria linked to health or disease. Key elements are a unique capability to isolate all bacteria from any individual, and the leading collection of bacterial genomes which is being expanded to comprise the definitive global collection. Together with AI, these capabilities enable identification of therapeutic bacteria and progression as oral therapies. The company has built an expert team of 35 scientists and is driving programs in C. difficile, Ulcerative Colitis and Immuno-oncology (bacterial co-therapy).

Contact: info@microbiotica.com | www.microbiotica.com

NEMESIS BIOSCIENCE

Nemesis Bioscience is a biopharmaceutical company developing Symbiotics® — DNA therapeutics administered before or with antibiotics to inactivate anti-microbial resistance in bacterial pathogens.

These Nemesis Symbiotics will make existing antibiotics work again, prevent the spread of resistance genes, and protect the efficacy of new antibiotics. The technology is applicable to all antibiotic classes, all known resistance mechanisms, and all bacteria.

To deliver the Symbiotics, Transmids®, our novel vectors, are encapsidated in a bacteriophage coat. Transmids can also spread directly between bacteria by conjugation.

Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.

Our current Symbiotics use RNA-guided endonuclease technology to inactivate multiple β-lactamase (bla) resistance genes — so resurrecting sensitivity to beta-lactams.

We have validated the efficacy of both Transmid delivery routes and of consequent AMR inactivation in mouse models (i) therapeutically in a bacterial infection and (ii) also prophylactically inactivating AMR in the gut flora.

Our multifunctional gene targeting systems may obviate the need for prior diagnostic screens for antibiotic resistance and be used generally as a companion biological therapeutic together with well-established antibiotics for therapeutic treatment of infection as well as for prophylactic treatment to prevent the spread of AMR.

Contact: massam@nemesisbio.com | www.nemesisbio.com
02h Discovery was founded in 2005 and has an integrated drug discovery platform operating from our state-of-the-art research centre in India and our office in Cambridge, UK. We have the in-house capability to execute hit-lead-optimisation programmes leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology and the on-going project management of pre-clinical development. 02h Discovery has developed and launched its proprietary application AI Chemistry in the Cloud™ — the world’s first app to revolutionise the project management of external drug discovery programmes. The app enables communication between the various scientific stakeholders essential to successful project advancement, leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the AI Chemistry in the Cloud™ app so that they can speedily execute tasks anytime, anywhere. The DNA of 02h is centered around the nurturing of its people, values and culture; it reflects the way we work with each other, as well as our collaborators and partners.

Contact: Tejas Upadhyay | tejas@02h.com
www.02h.com

OBrizum® Group Ltd. is a B2B corporate learning and knowledge management company. We are headquartered in Cambridge (UK) with satellite offices in London and South Korea. The company is structured in three divisions: OBrizum®, our award-winning artificial intelligence-driven eLearning and analytics software product; OBrizum® Media, our multimedia content production agency; and OBrizum® X, our blended corporate training and conferencing offering.

Contact: info@obrizum.com | www.obrizum.com
Oppilotech modelling methodology is different from traditional approaches (Flux Based Analysis) in that we go into a much higher level of detail incorporating parameters such as catalytic rates, metabolite levels and half-lives. The high level of detail allows us to reveal new biology and identify first-in-class non-intuitive drug targets. We initially focused our modelling efforts on *E.coli* identifying four first-in-class antibacterial drug targets and generated active chemical matter against three of them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells, allowing us to address a wider range of diseases. Oppilotech is actively seeking partnerships with pharma/biotechs/academic groups to model specific biological pathways to identify viable drug targets and new biology.

**Contact:** www.oppilotech.com

Pelago Bioscience AB was founded in 2013 to develop and provide services based on the patented Cellular Thermal Shift Assay (CETSA®). This assay is uniquely able to measure drug–target interactions *in situ* within the cellular environment and can be applied against a specified protein target for compound screening and lead optimization (CETSA Classics and CETSA HT) or in a non-targeted proteomics study (CETSA Mass Spec).

Critically CETSA requires no modification to the ligand or target as it utilizes the natural thermodynamic properties of the protein itself and can be applied to any cell or sample type. CETSA MS is ideal for un-biased proteomics studies and is now used routinely for determining compound liabilities and for mode of action studies. A recent development has been its use to identify novel biomarkers. Pelago works exclusively on CETSA and is able to offer full assay development and screening services to its customers, using its own dedicated laboratories in Sweden.

**Contact:** www.pelagobio.com
PhoreMost is a Cambridge UK-based biotech company, focused on its core goal of “Drugging the Undruggable™”. Founded in 2014, PhoreMost has developed its proprietary next-generation phenotypic screening platform SITESEEKER® which can discern the best new targets for future therapeutics and, crucially, how to drug them. This has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other diseases of unmet need.

PhoreMost’s internal oncology assets focus on key oncogenic drivers with previously undruggable targets currently being progressed including multiple K-RAS synthetic lethal targets. In partnership with Sentinel Oncology, PhoreMost is also progressing allosteric PLK1 inhibitors, currently in development for the treatment of Glioma. The pipeline is further bolstered by projects in diseases of ageing, neurodegeneration, and increasing efforts in the exciting field of targeted protein degradation.

In addition to internal programmes, PhoreMost collaborates with a range of pharma and biotech partners to enable access to its SITESEEKER platform. Through these collaborations — with companies including Boehringer Ingelheim, Otsuka, Oxford Biomedica, and C4X Discovery — PhoreMost works closely with its partners to screen pathways of interest and deliver validated targets with functional, binding peptides, suitable for entry into the drug discovery pipeline.

Contact: www.phoremost.com

Qkine is on a mission to advance stem cell, organoid and regenerative medicine research by re-defining industry standards for growth factor and cytokine quality, which are essential reagents for the sector.

Based on proprietary technology developed in the laboratory of Dr Marko Hyvönen, senior group leader at the University of Cambridge, Qkine manufactures highly pure bioactive recombinant proteins. Along with setting a new benchmark for protein purity, Qkine uses protein engineering techniques to tackle fundamental biological and scalability challenges that are holding back the stem cell and regenerative medicine sector; for example, recent projects have included development of optimised R-spondins to replace conditioned media for organoid culture.

To give stem cell scientists peace of mind, Qkine manufactures its proteins in a dedicated animal-derived component free (ADCF) laboratory and defines very strict and robust quality criteria, with detailed online data provided for every batch.

Contact: info@qkine.com | www.qkine.com
Repure Life Science INC. is a company based on person-centered human respect and trust with the meaning of “make your life pure again”. We already knew that cancer patients without drugs are suffering for treatment, so we established our company with cancer-related clinicians. We aim to improve the quality of healthy life through prevention and management, not just healing of diseases.

We are researching new drug development by integration of collected non-clinical data & clinical data and building a healthcare platform, and we want to add strength to many patients.

Additionally, we have currently completed an algorithm that provides exercise prescription solutions based on more than 70 disease cases. We are developing a platform linking diet and medication based on this data.

Repure Life Science INC. is making efforts to manage diseases, prevent diseases, and develop new drugs by building a platform that manages the life cycle assessment.

We work with leading experts to become a healthcare company that provides care, not just cure, to humans.

**Contact:** www.repurels.com

Sai Life Sciences is one of India’s fastest growing Contract Research, Development & Manufacturing Organizations. As a pure-play, full-service CRO-CDMO, it works with over a 100 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.

Over the past two decades, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. Today, it has over 2000 employees across its facilities in India, the UK and the USA.

In 2019, marking the completion of 20 years since inception, the company announced Sai Nxt, an organisation-wide transformation initiative and committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

The company has since added 172 KL API & Intermediate manufacturing capacity, opened a discovery biology Lab in Cambridge, Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK and an 83,000 sq. ft. integrated research & technology facility in Hyderabad. It became the first India-headquartered company to join the Pharmaceutical Supply Chain Initiative (PSCI).

**Contact:** www.sailife.com
Semarion addresses fundamental bottlenecks in the screening of adherent cells for drug discovery. Our SemaCyte® microcarrier platform revolutionizes in-vitro cell handling, offering orders of magnitude improvements in workflow efficiency. We are currently alpha testing our first minimal viable product, and are looking for biopharma, research, and CRO partners interested in partnering on the early testing of our platform.

At Semarion, we turn adherent cells into liquid reagents, an approach that is truly unique. SemaCytes® are flat microcarriers which are loaded with cells and then brought into suspension. This offers the convenience of liquid handling techniques to adherent cells while retaining their native state and morphology. This fundamental change to adherent cell handling allows the SemaCyte® platform to offer a ~10x improvement to three key workflow challenges in this space: (1) frozen adherent assay-ready cells to reduce the cell preparation time per assay by >20x to less than 1 hour, (2) cell-multiplexing or the ability to run an experiment on 10 cell types in the same culture well as opposed to a single cell type, and (3) a reduction in cell numbers needed per assay for scarce cell types by 10x from ~5,000 to 200-500.

Contact: www.semarion.com | info@semarion.com

Somaserve pioneers new therapies for crossing biological barriers including the BBB, targeting neuronal, malignant and immune system tissues using its innovative, leading-edge technology polyNaut®. Using proprietary, phenotypic targeting algorithms, cells of choice can be forensically targeted with ligands selected to bind to specific receptors expressed on the cell surface. Somaserve works across a wide range of modalities, including genetic material, biologics and small molecules.

Somaserve collaborates with pharma and biotech companies to enable promising molecules to reach the intended sites of action, thus solving drug delivery challenges. The company’s focus is to improve the therapeutic viability of molecules with poor pharmacokinetic and chemical properties.

The company is a UCL spin-out that has just completed an over-subscribed funding round. Amongst the investors are Abcam plc, our strategic marketing partner for non-clinical polyNaut products.

PolyNaut is a patented nanotechnology which delivers its cargo to the interior of the cell (through endocytosis), greatly enhancing therapeutic efficacy of encapsulated molecules.

The surface of the nanoparticle vesicle can be functionalised with peptide ligands to engineer binding, combining multivalency, steric control and multiplexing boosting penetration of biological barriers and delivering directly to cells of interest.

The polymers used are classified as GRAS or approved excipients. Metabolism yields simple compounds that are readily excreted. The basic technology has been transferred to GMP facilities for scale up.

Contact: info@somaserve.com | www.somaserve.com
Standigm is a drug discovery company that searches for therapeutic lead compounds using advanced artificial intelligence (AI) methods trained on big biomedical data. Standigm research spans from target identification to drug design.

We have proprietary AI platforms encompassing novel target identification to lead generation. Standigm ASK™ is a customizable novel target identification platform applying deep neural network inference and prediction on a comprehensive knowledge graph, and Standigm BEST™ is an automated and industry-level AI platform for lead generation. We have established an early-stage drug discovery workflow with these platforms and are running drug pipelines by ourselves or with collaborators using the workflow. We are seeking further partners interested in discovering novel targets and therapeutic compounds based on insight from AI.

Founded in 2015 by experts in artificial intelligence and systems biology at Samsung Advanced Institute of Technology, Standigm has grown into a team of 54 members, including researchers (53% Ph.Ds among 40 R&D members) of multi-disciplinary expertise in AI science and engineering, chemistry, biology, and pharmacology. Standigm has raised a total of $60 million in funds, including its current pre-IPO funding. We will use the funds to scale the AI technology platforms and advance our drug discovery pipelines toward license-out. Our vision is a full-stack pharmaceutical company that could ease the pain of patients all over the world.

Contact: business@standigm.com | www.standigm.com

Storm Therapeutics is a spin-out of the Gurdon Institute at the University of Cambridge, created to commercialise the work of founders Professors Tony Kouzarides and Eric Miska in RNA epigenetics.

Several large families of RNA-modifying enzymes have been identified that impact key biological processes by changing the activity of RNA through catalysing epigenetic RNA modifications. Storm is working at the forefront of this new field, collaborating closely with our scientific founders and their research groups at the Gurdon Institute to elucidate the functional role of diverse RNA modifications. Advances in the understanding of RNA modification and its role in the development of cancer offer the prospect of identifying novel therapeutic targets. Using cutting-edge techniques such as CRISPR screens, chemical biology, RNA-Seq and RNA mass spectrometry, we have established a unique target discovery platform for the identification of small molecule modulators of RNA modification pathways.

Since inception in May 2015, Storm has raised £16m in seed and Series A funding. The company uses the proceeds to establish a pipeline of drug discovery programmes to develop novel, first-in-class drugs for the treatment of specific cancers with high unmet medical need.

Contact: info@stormtherapeutics.com | www.stormtherapeutics.com
TOTIENT

Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer, collected from patients experiencing exceptional immune responses. Unlike antibodies generated in a transgenic mouse, Totient antibodies are discovered by interrogating the patient's natural immune response during the course of a certain human disease. This allows Totient to discover both antibodies and human target antigens at the same time for a certain indication.

Our human-derived antibodies are high affinity and highly specific to tissue-specific antigens, and are well suited for cell therapies, ADCs, and bispecifics.

Contact: contact@totient.bio | www.totient.bio

TWIST BIOSCIENCE

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Contact: www.twistbioscience.com
Vernalis Research, a HitGen Company, is recognised as a world leader in fragment- and structure-based drug discovery. Based in Cambridge, UK, Vernalis has been developing and applying these methods to challenging projects since 1997.

Vernalis has a strong emphasis on combining innovative structural biology, biophysics, and medicinal chemistry to solve problems and tackle targets across therapeutic areas, ranging from oncology to inflammation and CNS disorders. This requires a deep understanding of the techniques involved and a cautious interpretation of the data; an approach grounded on over two decades of developing and applying fragment-based lead discovery to a wide range of therapeutic targets.

By combining structural, thermodynamic, and kinetic information from fragment and other hits, we design novel, potent, drug-like molecules. Our successes include generation of lead compounds which inhibit protein–protein interactions and enzymes, leading to pre-clinical candidates for Mcl-1, Bcl-2, Hsp90, FAAH, Chk1 and IRAK4.

Vernalis balances an internal portfolio of drug discovery projects with fully integrated research collaborations with academic partners, and biotechnology and pharmaceutical companies.

Contact: collaborate@vernalis.com | www.vernalis.com

Virokine Therapeutics Ltd (VTL) t/a Virothera is a start-up preclinical stage biotech developing novel cytokine gene therapy and other immune treatments for infectious and inflammatory diseases. Our novel platform technologies – VLM (virus like membranes) and VLT (virokine immune therapeutic) – use genes encoding antigens and cytokine immune modulators for new cures.

Our first candidate is a thermostable DNA vaccine making RNA in vivo to reprogram protective immunity. This asset is for HSV, a leading STD worldwide, and is funded by NIH/NIAID for IND-enabling preclinical model in vivo studies in USA. Results show complete protection against acute infection, affecting latency recurrence. This also supports a novel host therapeutic for COVID.

Our team includes a founder Professor, initially at Cambridge then London School of Hygiene & Tropical Medicine, highly experienced Directors in Corporate Finance and BD, expert scientific advisory Board from Oxford, Stanford and NIHR, and exceptional lab staff. Over the last year, we filed our fully Company owned patents and successfully completed our first preclinical program. Over the next year, we plan to advance our lead candidates to the clinic. We are based at the London Bioscience Innovation Centre adjacent to the Royal Veterinary College and the Francis Crick Institute, and are honoured to continue as affiliates of the Milner Therapeutics Institute at Cambridge.

Contact: info@virokine.com | www.lbic.com/virokine
Vivan Therapeutics, a UK based company, offers personalised cancer therapeutics utilising technology developed at and in partnership with Mt Sinai Medical Center. We identify personalised cancer treatments for patients based on their tumour genetics. For each patient, we build a genetically matched fruit fly model of the tumour, which is used for large-scale drug screening to find novel and effective drug combinations. This platform can treat even difficult cancers with combinations of approved drugs. Nearly all combinations incorporate non-cancer drugs, making them less toxic and more affordable. Using our proprietary screening data, we are building a powerful AI-driven digital health tool, which can predict effective treatment options rapidly. Our in vivo, high throughput drug screening platform is also used to power biopharma discovery and development.

Contact: laura@vivantx.com | www.vivantx.com
AFFILIATED RESEARCH INSTITUTIONS

The Affiliated Research Institutions programme, established in October 2017, now includes 14 academic institutions across four continents. These partners share our vision of developing new models for research collaboration across industry and academia to transform pioneering science into therapies.
BIO-SYNERGY RESEARCH CENTER (BSRC), KAIST

As a Korean national research center, BSRC has been developing a virtual human system called CODA, with which we can explore potential efficacy and candidate mode-of-action pathways of single or combination drugs, and natural product-derived medicinal extracts. CODA contains more than 50 million physiological associations among genes, metabolites, cellular functions, and phenotypes in a unified XML-like format called CODA-ML. BSRC has been applying this system to develop combination drugs and functional foods in collaboration with several Korean pharmaceuticals and food companies.

Contact: http://biosynergy.re.kr/english

CRUK OXFORD CENTRE

Established in 2010, the CRUK Oxford Centre (formerly the Oxford Cancer Research Centre) is a network and partnership between Oxford University, Oxford University Hospitals NHS Trust and Cancer Research UK, based on the University’s Translational Biomedical Research Campus. It harnesses Oxford’s world-leading cancer research with the core aim of facilitating collaboration to ensure rapid translation from scientific discovery to treatments for patients.

The ultimate aim of the Centre is to enhance cancer research activity to increase cancer cure rates. The Centre currently comprises over 500 members from 25 different Departments, Units, Institutes of the University as well as the NHS Trust. The partnership provides a cumulative investment of approximately £55m each year for science in Oxford for research to save and improve peoples’ lives.

The Oxford Centre is an inclusive network of organisations in Oxford for whom cancer research is a priority focus. We support and connect people working across a range of disciplines and aim to facilitate research collaboration on a local, national and international scale to speed up translation from scientific discovery to treatments in patients.

Contact: www.cancercentre.ox.ac.uk
The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence located in Barcelona, Spain, whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity.

CRG believes that the medicine of the future depends on the ground-breaking science of today. The breadth of topics, approaches and technologies at CRG permits a broad range of fundamental issues in life sciences and biomedicine to be addressed. Research at CRG falls into four main areas: gene regulation, stem cells & cancer; cell & developmental biology; bioinformatics & genomics; and systems biology.

With around 500 scientists from 41 nationalities and ranking 5th worldwide in research quality, the CRG excellence is based on an interdisciplinary, motivated and creative scientific team that is supported by high-end and innovative technologies.

CRG offers numerous and varied (often unique) possibilities for collaboration in various areas of human health and personalized medicine (e.g. novel targets and mechanisms in oncology; exosomes and genome sequencing; tissue regeneration and engineering; and the study of the microbiome), as well as access to cutting-edge expertise and infrastructure for Advanced Light Microscopy, FACS, Genomics, Proteomics, Bioinformatics, Screening/Protein Technologies and Tissue Engineering. Since 2015 the CRG also integrates the National Centre for Genomic Analysis (CNAG), the 2nd largest centre in sequencing capacity in Europe. Tools and technologies are also available for partnering and licensing in the fields of cancer and immunology, lung and infectious diseases, rare diseases, neurodegeneration, protein engineering, regenerative medicine and vaccination.

Contact: www.crg.eu

The Spanish National Cancer Research Centre (CNIO) is a world-class centre for basic and translational cancer research located in Madrid. Our mission is to gain knowledge and apply it to prevent, diagnose and treat cancer, with over 450 researchers at the forefront of cancer research.

The CNIO ranks in second position for monographic cancer centres in Europe and our expertise and capabilities extend to ageing and oncology. Nurturing an ecosystem for translational research and innovation, we help researchers maximize the value of their science and bring their discoveries to society as new technologies and therapies.

A strategy to accommodate different partnership models with industry and facilitate knowledge transfer is at the core of our goals. We have a dedicated Academic Drug Discovery Programme with the expertise to carry out chemical validation of potential new targets and development of lead compounds into preclinical drug candidates.

Our current portfolio includes 8 active proprietary programs in oncology, and our value in drug discovery is supported by our unique research with genetically-modified and xenografts disease mouse models and our state-of-the-art biotechnology units. CNIO investigators are leaders in oncology and ageing (regenerative medicine) with special emphasis in DNA damage, cell cycle and telomeres, metastasis and microenvironment, inflammation and immunomodulation, metabolic disorders and fibrosis, gene therapy, breast cancer, prostate cancer, melanoma, brain cancer, haematological tumours and lung cancer.

The CNIO seeks public-private research partnerships and licensing of a number of small molecule discovery programs at the hit-to-lead or lead optimization stage.

Contact: www.cnio.es
The Electronics and Telecommunications Research Institutes (ETRI), as the Federal Research Agency of Korea for ICT and related technologies, has launched the Cognitive Informatics Research Program, as a strategic institutional agenda, for research and development of novel technologies to enable cognitive reasoning in artificial intelligence.

The human civilization is going through another technological revolution, which is referred to as The 4th Industrial Revolution, to augment our mental capabilities while the previous industrial revolutions were aimed to augment our physical capabilities.

CybreBrain consists of a set of novel ICT technologies to enable The 4th Industrial Revolution, with focus on the self-adaptive real-time Artificial Intelligence. This self-adaptive artificial intelligence with plasticity is capable of deductive reasoning, real time inferencing from in-motion data as well as at-rest data, progressive and incremental learning from outcomes, and self-adaptation to new findings and decision making.

The R&D approach we are taking is to reconstruct and simulate the human brain for cognitive reasoning, prediction and prescriptive decision making by reverse engineering the cerebral cortex of the human brain. We call this novel machine learning and artificial intelligence system “The Thinking Machine” or “CybreBrain”.

Contact: www.etri.re.kr/eng/main/main.etri

The Institute of Cancer Research, London, is an independent research institute based across two London sites: one in Chelsea in the heart of the UK capital, and one in Sutton, 30 minutes from Gatwick international airport. A member of the University of London, we have an outstanding record of achievement dating back more than 100 years.

Around 800 scientists work at the Institute, across the full spectrum of cancer research: from basic cancer biology and drug discovery to clinical trials. We also have a unique partnership with The Royal Marsden NHS Foundation Trust: together, we are rated in the top four centres for cancer research and treatment worldwide.

The Institute of Cancer Research (ICR) is ranked top for research, research impact, biological sciences, clinical sciences and research intensity in the definitive REF rankings of UK university research. We are also world-leading in the commercialisation of our research, seeing collaboration with industry as a vital component of our success.

We have more than 200 active partnerships with a range of companies, from small, specialised biotech and MedTech firms to big pharma. We are consistently ranked by international league tables as one of the world’s most successful higher education institutions for academic innovation and effective collaboration with industry.

We are also among the top 10 universities worldwide for the proportion of our papers published with industry, and are first globally for the proportion of academic papers cited in patent applications.

Contact: www.icr.ac.uk
INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB BARCELONA)

IRB Barcelona is a world-class research centre devoted to understanding fundamental questions about human health and disease. It was founded in October 2005 by the Government of Catalonia (Generalitat de Catalunya) and the University of Barcelona (UB), and is located at the Barcelona Science Park (Parc Científic de Barcelona). IRB Barcelona forms part of the Barcelona Institute of Science and Technology.

The Institute’s missions include conducting multidisciplinary research of excellence at the unique interface between biology, chemistry and medicine, providing high-level training in the biomedical sciences to staff, students and visitors, driving innovation through active technology transfer to the benefit of society, and actively participating in an open dialogue with the public through a series of engagement and education activities.

Exceptional scientific results deserve to be transferred to society. With this in mind, IRB Barcelona has devised a proactive strategy to ensure that the discoveries made in its labs are developed into products and technologies that serve the scientific and healthcare communities, as well as society at large.

Advised by an international Business Advisory Board, specialists from the Innovation Department work shoulder to shoulder with our researchers to identify results with commercial potential and to protect, develop and commercialize them, with the aim to establish strategic public-private sector collaborations, licensing agreements, and spin-off companies.

Contact: www.irbbarcelona.org/en

JOHNS HOPKINS UNIVERSITY & MEDICINE

Johns Hopkins Technology Ventures (JHTV) is the intellectual property administration center of The Johns Hopkins University. In addition to serving as the licensing, patent and technology commercialization office for Johns Hopkins researchers and inventors, JHTV also supports the growth of start-up companies in and around the university and is an active liaison to parties interested in leveraging university research or materials for academic or corporate endeavours.

JHTV aims to maximize the impact of The Johns Hopkins University’s research excellence by facilitating the translation and commercialization of discoveries into accessible technologies, products and services that benefit society.

Contact: ventures.jhu.edu
MEDICINES DISCOVERY CATAPULT

The Medicines Discovery Catapult is a national centre of applied Research and Development expertise, uniquely designed to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects.

It is one of a network of elite, not-for-profit technology and innovation centres established by Innovate UK as a long-term investment in the UK’s economy. The Medicines Discovery Catapult will work with industry, academic teams, technology experts, charities, regulators and others.

We provide unique scientific capabilities and act as a gateway to specialist facilities, technology and expertise within the UK, supporting SMEs to drive the development of new approaches for the discovery and early development of new medicines. Helping to transform ideas into commercial products and services for the wider health and wealth of the country.

By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, it can help the UK maintain its heritage position as a global leader in this key industry.

Contact: md.catapult.org.uk

PETE R MACCALLUM CANCER CENTRE

Peter MacCallum Cancer Centre is Australia’s only public hospital solely dedicated to caring for people affected by cancer and is one of the world’s leading cancer research, education and treatment centres. We have over 2,500 staff, including more than 580 laboratory and clinical researchers. We aim to lead a new era of cancer prevention, care and discovery, supported by state-of-the-art facilities at our new home within the Victorian Comprehensive Cancer Centre building.

The Peter MacCallum Cancer Centre houses the largest group of laboratory-based cancer researchers in Australia working in close collaboration with multi-disciplinary teams comprising medical, surgical and radiation oncologists, nurses, radiation therapists and allied health professionals. We offer industry a range of opportunities for collaborative research and development across the spectrum from discovery through to clinical trials. Our laboratory scientists offer pre-clinical drug development expertise, with access to sophisticated animal models of cancer, cutting edge genomic facilities and a range of human tissue banks. Many of our laboratories have also pioneered new technologies in-house that are open to licensing and further development.

65+ years after our establishment, this sense of purpose and commitment to making life better for people affected by cancer continues at our centre today.

Contact: www.petermac.org
**SAAMSUNG GENOME INSTITUTE**

Personal genome information is essential for patient care in a precision medicine clinic. The Samsung Genome Institute (SGI) is mainly working on cancer genomics to understand tumor heterogeneity and microenvironment. CancerSCAN is a diagnostic service for precision cancer medicine with comprehensive annotation on any variant in patients. We provide information about the treatment response to each variant in certain tumor types in the Samsung Medical Center (SMC). CancerSCAN analyzes 377 cancer-related genes for SNV, Indel and CNV and also 661 genes for gene fusions and immune profiling. Until now, we have analyzed more than 10,000 cases, which is also linked to a patient’s clinical information through a clinical data warehouse in SMC (*Nature Communications*, 2017). Based on frequent somatic mutation in SMC patients, we designed a focused NGS panel for circulating tumor DNA liquid biopsy (*Genome Biology*, 2017). We have designed cancer type-specific panels to maximize the detection sensitivity for tumor monitoring in clinical trials in SMC. Single cell genome analysis provides invaluable information about the tumor microenvironment in patients.

We found cell-type markers for immuno-therapy in lung, colon and breast cancer (*Nature Communications*, 2017; *Nature Genetics*, 2017). We are also working on undiagnosed disease in the neonatal intensive care unit to uncover pathogenic mutations in sick babies. The clinical sequencing lab operates four Illumina sequencers and a Oxford Nanopore with a CAP-accredited pathology lab. The bioinformatics lab provides an analysis pipeline, and also runs projects on cancer genomics. We are now interested in the utility of clinic-genomic data for the discovery for drug targets.

**Contact:** www.samsunghospital.com/gb/language/english/main/index.do

---

**SYLVESTER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF MIAMI HEALTH SYSTEM**

Since its inception as a dedicated, comprehensive cancer center, then significantly supported by a naming gift from the Harcourt M. and Virginia W. Sylvester Foundation, Sylvester Comprehensive Cancer Center (UM/Sylvester) has been the cancer brand for the University of Miami Leonard M. Miller School of Medicine. As the only university-based cancer center in South Florida, Sylvester has transformed cancer research and treatment in South Florida and beyond.

We seek to reduce the human burden from cancer and other serious illnesses through research, education, prevention, and the delivery of quality patient care.

- Sylvester will become a fully integrated program of patient care, education, and research with an international reputation for excellence.
- Sylvester will provide new hope for cancer patients in our extended community, which includes South Florida, the southeastern United States, the Caribbean, and South America.
- Sylvester will promote efficient, community-responsive health care, and generate resources to sustain and enhance innovative cancer programs.
UNIVERSITY OF PENNSYLVANIA: PENN CENTER FOR INNOVATION

As the nation’s first medical school and home to the first teaching hospital, the Perelman School of Medicine (Penn Medicine) has a long tradition of academic excellence and scientific discovery. Building on this tradition, our innovative, interdisciplinary research programs continue today to pave the way for a future of new paradigms in cutting-edge science.

As an internationally renowned community of scientists and physicians, we are dedicated to both advancing knowledge and fostering a culture of excellence in training the next generation of scientific leaders. Our faculty are at the forefront of the biomedical revolution, and we are committed to sustaining a vibrant intellectual environment, with the ultimate goal of translating ground-breaking discoveries into medical therapies that will eradicate disease and improve health care around the world. The Penn Centre for Innovation (PCI) helps to translate Penn discoveries and ideas into new products and businesses for the benefit of society by facilitating connections with the private sector. Whether the end result is a technology license, an R&D alliance, the formation of a new venture, or an integrated combination of these activities, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.

Contact: pci.upenn.edu

YONSEI UNIVERSITY COLLEGE OF MEDICINE

The history of the Yonsei University College of Medicine starts from the opening of “Kwanghyewon” in 1885. Kwanghyewon was established to provide western-style medical treatment to the people of Chosun (Korea’s former name) suffering from disease, as well as to serve as a teaching facility for its youth to learn western medicine and sanitary science. Then in 1886, the Chejungwon Medical School was established and formalized medical education began. As Korea’s first institution of western medicine, our College of Medicine has been a leader in medicine here for the past 120 years.

In order to create a leading medical college, we are striving to provide an environment where researchers can passionately achieve their greatest potential. In addition, to further develop our education and research potential, we will expand the college’s essential support functions, as well as distribute and apply resources in the most efficient manner.

Ultimately, it is our goal to increase the level of medical education and services in order to become a hub medical institution in the world. We will do this by identifying the most capable individuals at our institution, supporting research and continuing our efforts to lead the way in the latest methods in clinical treatment.

Contact: medicine.yonsei.ac.kr/medicine-en/index.do
Bringing discoveries to life